✦ LIBER ✦

A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma

✍ Scribed by Aminah Jatoi; Neil Ellison; Patrick A. Burch; Jeff A. Sloan; Shaker R. Dakhil; Paul Novotny; Winston Tan; Tom R. Fitch; Kendrith M. Rowland; Charles Y. F. Young; Patrick J. Flynn

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 115 KB
Volume: 97
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.11200

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. this phase ii trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma.

Methods:

This study, which was conducted by the north central cancer treatment group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (psa) elevation with hormone therapy. continued use of luteinizing hormone-releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long-acting antiandrogen therapy in the preceding 6 weeks. patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. each dose contained 100 calories and 46 mg of caffeine. patients were monitored monthly for response and toxicity.

Results:

Tumor response, defined as a decline >/= 50% in the baseline psa value, occurred in a single patient, or 2% of the cohort (95% confidence interval, 1-14%). this one response was not sustained beyond 2 months. at the end of the first month, the median change in the psa value from baseline for the cohort increased by 43%. green tea toxicity, usually grade 1 or 2, occurred in 69% of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. however, six episodes of grade 3 toxicity and one episode of grade 4 toxicity also occurred, with the latter manifesting as severe confusion.

Conclusions:

Green tea carries limited antineoplastic activity, as defined by a decline in psa levels, among patients with androgen independent prostate carcinoma.

📜 SIMILAR VOLUMES

Phase II trial of cyclophosphamide, vinc

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma

✍ Danai D. Daliani; Vasily Assikis; Shi-Ming Tu; Christos N. Papandreou; Lance C. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

## Abstract ## BACKGROUND In this Phase II study, the authors assessed the toxicity and anti‐tumor activity of a combination of oral cyclophosphamide, oral low‐dose dexamethasone, and intravenous vincristine (CVD) in patients with metastatic androgen‐independent prostate carcinoma (AI‐PCa). ## ME

Selective aromatase inhibition for patie

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma : A Phase II study of letrozole

✍ Matthew R. Smith; Donald Kaufman; Daniel George; William K. Oh; Maryanne Kazanis 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

## Background: First and second-generation aromatase inhibitors have shown activity in patients with androgen-independent prostate carcinoma. these early-generation aromatase inhibitors are nonselective, however, and inhibition of other steroidogenic enzymes may contribute to their reported clinica

Phase II evaluation of docetaxel plus on

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

✍ Victoria J. Sinibaldi; Michael A. Carducci; Sandra Moore-Cooper; Menachem Laufer 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB 👁 1 views

Diethylstilbestrol and docetaxel : A pha

Diethylstilbestrol and docetaxel : A phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer

✍ R. Bruce Montgomery; Peter S. Nelson; Daniel Lin; Christopher W. Ryan; Mark Garz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract ## BACKGROUND. The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial. ## METHODS. Twenty‐nine patients w

A Phase I/II study of strontium-89 combi

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

✍ Lance C. Pagliaro; Ebrahim S. Delpassand; Dallas Williams; Randall E. Millikan; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract ## BACKGROUND The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium‐89 to patients with androgen independent prostate carcinoma. ## METHODS Patients with androgen‐independent pr

Multicenter Phase II study of estramusti

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma

✍ David J. Vaughn; Archie W. Brown Jr.; W. Graydon Harker; Sang Huh; Lance Miller; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Patients with progressive AIPC received 90 mg/m^2^ paclitaxel by 1‐ho